- “Salbutamol + Theophylline Tablets” already exists in your wishlist
In Stock
Osimertinib Tablets
Osimertinib Tablets 80mg | Anti-Cancer
- Product Form: Raw Powder / API
- Not for direct consumer use
- For qualified buyers, formulation, compounding, R&D, and regulated business use only
- COA/MSDS available upon request
- Final sale depends on buyer country import regulations
Disclaimer: Products listed on this website are intended for qualified business buyers, research, formulation, compounding, or regulated pharmaceutical use only. Products are not intended for direct consumer use. Import permission, registration, customs clearance, and local regulatory compliance are the responsibility of the buyer in their respective country.
Description
Generic medicine information • For patient education
Product Introduction
Osimertinib 80 mg is a prescription anti-cancer medicine in the tyrosine kinase inhibitor (TKI) class. It is used for selected adults with non-small cell lung cancer (NSCLC) whose tumour has specific EGFR (epidermal growth factor receptor) mutations. A clinician may order a tumour test to determine whether this treatment is appropriate.
Treatment decisions, dose changes, and monitoring must be managed by an oncology specialist. Do not start, stop, or change the dose on your own.
1. Uses
Used to treat certain types of non-small cell lung cancer (NSCLC) in adults with specific EGFR mutations, according to the indication and treatment plan selected by the treating oncologist.
Eligibility depends on the cancer diagnosis, tumour test results, treatment history, and current approved prescribing information.
2. Benefits
Targets abnormal EGFR signalling involved in the growth and spread of some cancer cells.
In eligible patients, it may help control the cancer, shrink tumours, or delay disease progression. The expected benefit varies by the individual and treatment setting; it is not a guaranteed cure.
3. Side Effects
Common or reported effects may include diarrhoea, rash, dry skin, mouth inflammation (stomatitis), fatigue, reduced appetite, nail changes, muscle/joint/bone pain, and changes in blood counts such as anaemia, low white blood cells, or low platelets.
Serious but less common risks can include inflammation of the lungs (interstitial lung disease/pneumonitis), heart muscle problems, abnormal heart rhythm or QT prolongation, severe skin reactions, and rare severe bone-marrow problems.
Seek urgent medical advice for new or worsening shortness of breath, cough or fever; chest pain, fainting or a fast/irregular heartbeat; severe or blistering skin rash; unusual bleeding or bruising; or severe/persistent diarrhoea or dehydration.
4. Safety Advice
Pregnancy: may harm an unborn baby. Tell the oncology team before treatment if pregnant, planning pregnancy, or if pregnancy is possible. Follow the specialist’s advice on effective contraception during treatment and for the recommended period after the last dose.
Breastfeeding: generally not recommended during treatment and for the recommended period after the last dose; confirm the exact interval with the treating specialist.
Heart and lung monitoring: attend all scheduled checks. Tell your clinician about heart rhythm problems, heart failure, lung disease, or previous severe treatment reactions.
Kidney or liver disease: tell your clinician; monitoring or treatment decisions may need adjustment.
Alcohol: ask your oncology team whether alcohol is appropriate during treatment.
Driving: do not drive or operate machinery if you feel dizzy, sleepy, visually impaired, or otherwise unwell.
Store below 30°C, in the original packaging and out of reach of children, unless the product label says otherwise.
5. How It Works
Osimertinib blocks abnormal EGFR tyrosine kinase signalling in cancer cells that carry susceptible EGFR mutations. This can slow or stop signals that help those cells grow and divide.
6. How to Use
Take exactly as prescribed by your oncologist. The prescribed regimen is often once daily, but follow your own prescription and current product leaflet.
May be taken with or without food. Try to take it at the same time each day.
Swallow the tablet whole with water. Do not crush, chew, or split it unless your treating team gives specific instructions.
If you miss a dose, follow the patient leaflet or contact your oncology team for advice; do not take an extra dose to make up for a missed one.
If you vomit after taking a dose, do not take an additional dose unless your oncology team tells you to.
Do not stop treatment or change the dose without speaking to your oncologist.
7. Quick Tips
Keep a current list of all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements and share it with your oncology team.
Check before starting any new medicine or supplement. Some medicines can affect osimertinib levels or increase heart-rhythm risks. Avoid St John’s wort unless your specialist specifically approves it.
Ask your care team about grapefruit or grapefruit juice and follow their advice.
Drink fluids if diarrhoea occurs, and contact your care team if it is severe, persistent, bloody, or accompanied by dehydration.
Protect skin from excessive sun exposure and report severe rash or skin peeling.
Attend recommended blood tests and heart/lung assessments.
8. Drug Interactions
Important interactions can occur with strong CYP3A-inducing medicines (which may reduce osimertinib exposure), some antifungals and other medicines, and drugs that prolong the QT interval or affect heart rhythm.
Do not start or stop medicines such as rifampicin, certain anti-seizure medicines, St John’s wort, selected antifungals, or heart-rhythm medicines without professional review. This is not a complete list.
Give your oncologist and pharmacist a complete list of all medicines and supplements. They can check the exact combination and advise whether monitoring or changes are needed.
Medical Disclaimer
This document is for general patient education only and is not a substitute for advice from a qualified doctor, oncology specialist, or pharmacist. Osimertinib is a potent prescription anti-cancer medicine and must be used only under specialist supervision. The correct indication, dose, monitoring, precautions, and management of side effects depend on the individual patient and the current approved product information. In an emergency, seek urgent medical care.
| Product Name | Osimertinib Tablets |
| Category | All Medicines, Anti Cancer |
| Form | Raw Powder |
| Grade | As per available specification |
| Documents | COA, MSDS, Invoice, Packing List |
| Packing | As per order quantity |
| MOQ | On request |
| Shipment | Air cargo / courier / buyer-approved route |
| Use | B2B, formulation, compounding, research & qualified buyer supply |
| Disclaimer | Subject to buyer country regulations |
Additional information
| Strength | 80mg |
|---|
Customer Reviews
Only logged in customers who have purchased this product may leave a review.
